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Abstract
Phosphorylation is one of the major mechanisms by which the activities of protein factors can be regulated. Such
regulation impacts multiple key-functions of mammalian cells, including signal transduction, nucleo-cytoplasmic
shuttling, macromolecular complexes assembly, DNA binding and regulation of enzymatic activities to name a few.
To ensure their capacities to replicate and propagate efficiently in their hosts, viruses may rely on the
phosphorylation of viral proteins to assist diverse steps of their life cycle. It has been known for several decades
that particles from diverse virus families contain some protein kinase activity. While large DNA viruses generally
encode for viral kinases, RNA viruses and more precisely retroviruses have acquired the capacity to hijack the
signaling machinery of the host cell and to embark cellular kinases when budding. Such property was
demonstrated for HIV-1 more than a decade ago. This review summarizes the knowledge acquired in the field of
HIV-1-associated kinases and discusses their possible function in the retroviral life cycle.
Review
The genetic information of human immunodeficiency
virus type 1 (HIV-1) is carried by an RNA genome of
approximately 9.3 Kb packaged into viral particles as a
non-covalent dimer [1]. This genetic material contains
nine open reading frames that encode fifteen proteins,
including structural proteins (matrix, capsid, nucleocapsid
and p6), envelope glycoproteins (gp120 and gp41) and
enzymes (protease, reverse transcriptase and integrase).
Six additional open reading frames direct the synthesis of
accessory and regulatory proteins (Tat, Rev, Nef, Vpr, Vpu
and Vif). These proteins have complex functions and gen-
erally interface with the host cell machinery. The mature
structural proteins and enzymes, Vpr, Nef and Vif are con-
tained in a spherical particle surrounded by a lipid bilayer
acquired from the host cell plasma membrane containing
the envelope glycoproteins. Early after HIV-1 discovery,
the particle was also proven to package components from
the host cell. The first studies performed using classical
biochemistry together with more recent analysis relying
on systematic mass spectrometry sequencing have inven-
toried the presence of a wide variety of cellular proteins in
highly purified HIV-1 virions [2,3]. While a fraction have
been reported to be required for viral infectivity, a propor-
tion of these components appear to be non-essential for
replication in a new target cell. The presence of cellular
proteins with varying functional importance in viral parti-
cles may reflect differences in the mechanisms accounting
for the viral incorporation of these host factors. Indeed, at
later replication stages, HIV-1-encoded proteins are direc-
ted to the site of assembly and form a bud consisting of
cellular membranes and cytoplasm. This particular step
favors the passive incorporation into HIV-1 virions of host
cell factors constitutively located at the plasma membrane
or present in the cytosol beneath the budding bilayer.
Alternatively, the budding particle incorporates cellular
factors attracted to the assembly site through specific
interactions with viral components. This last model is par-
ticularly illustrated by the packaging of cofactors assisting
late retroviral replication, including proteins from traffick-
ing systems ensuring targeting of viral proteins and nucleic
acids to the budding site, cofactors required for viral
assembly and cellular complexes involved in the budding
and release of the retroviral particle. An informative
approach to differentiate between these two classes of
virus-associated cell factors was proposed by Hammar-
stedt and Garoff [4]. By measuring the concentrations of
cellular proteins relative to the lipid content in the viral
particles and in the membranes of donor cells expressing
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number of factors selectively enriched in the viral particle
and those passively packaged into HIV-1. Using this strat-
egy, the increased concentration of cyclophilin A and
Tsg101 observed at the plasma membrane upon Gag pre-
cursor expression suggested a selective recruitment into
viruses rather than a passive incorporation. On the con-
trary, actin and clathrin appeared to “diffuse” into virions
because their respective concentrations at the membrane
remained unchanged regardless of whether Gag was
expressed. Considering the cellular proteins selectively
attracted into HIV-1 particles through interactions with
viral proteins or nucleic acids, their requirement for pro-
pagation in a new target cell is also variable. Indeed, a
number of packaged cell factors, including those recruited
to support late replication, have been assumed to be non-
essential to the early intracellular steps of replication. Con-
versely, some cellular proteins that have no proven role in
late replication, and are actively recruited into HIV-1, are
strictly required for propagation in a new target cell. A
number of these components have been shown to assist
the intracellular steps of future infectious cycles that are
not fully ensured by the HIV-1-encoded proteins. Encapsi-
dation and subsequent delivery of these proteins to the
target cell are supposed either to compensate for the lack
of essential cellular cofactors or to render them available
at the site which supports replication even if expressed in
the cell. An interesting approach to question the func-
tional importance of packaged cellular proteins is to inves-
tigate their capacity to be incorporated into particles of
HIV-1-related viruses. Comparative studies showed that
several proteins already found to be packaged into HIV-1
particles through specific interactions with viral proteins
or nucleic acids are also detected in HIV-2 and in simian
immunodeficiency virus (SIV) particles (see Table 1 for
references). For some proteins (discussed below), their
conservation was extended to more distant retroviruses,
such as HTLV-1. The significance of such similarities is
questionable. It may be either argued for the conservation
of a common mechanism of replication throughout viral
evolution, or it may be considered as a proof for the non-
specific association of proteins with distantly related
viruses. In a number of cases, including for some kinases,
evidence for the conservation of interaction motives in
viral proteins together with functional studies of viruses
unable to package these cellular factors proved that these
components retain an evolutionarily conserved function
[5-9].
Experimental strategies for the identification of
HIV-1-associated proteins
In addition to the difficulty associated with discriminat-
ing between host factors that are selectively or passively
packaged into viruses, the identification of cellular
proteins embedded in viral particles is technically com-
plicated. The most critical aspect is the strict necessity
to discriminate between virus-incorporated components
and cellular factors contaminating viral preparations.
The latter group includes proteins docked to the outside
of cell-free virions. This group also comprises cellular
proteins contained in microvesicles and exosomes with
sizes and densities comparable to viruses, that co-sedi-
ment with viral preparations and represent a source of
contamination even after the density gradient separation
of viral particles [3,10,11]. Accordingly, sample prepara-
tion should be performed carefully. Two reference pro-
tocols have been developed to produce preparations of
Table 1 Virion-associated cellular proteins in HIV-1, HIV-2
and SIV
Cellular proteins Virus
HIV-
1
HIV-2 SIV
Chaperone Hsp70 +
[32]
+ [32] + [32]
Cyclophilin
A
+
[26]
-
[26,124]
-/+
a
[26,124]
Pin 1 +
[37]
ND +[ 5 ]
Cytoskeleton Actin +
[37]
ND +[ 5 ]
Moesin +
[37]
ND +[ 5 ]
Ezrin +
[37]
ND ND
Arp2/3 +
[37]
ND +[ 5 ]
Vacuolar sorting Tsg101 +
[83]
+ [125] ND
Alix +
[84]
ND + [84]
Ubiquitin +
[37]
ND + [126]
Nucleic acids
binding
UNG2 +
[47]
- [127] - [127]
APOBEC3G +
[46]
ND + [128]
Staufen +
[43]
+ [43] + [43]
INI1/HSNF5 +
[42]
- [42] - [42]
Kinases ERK2 +
[6,7]
ND +[ 5 ]
PKA +
[14]
ND +[ 5 ]
a incorporated in some SIV strains (SIVcpz)
ND: not determined.
Giroud et al. Table 1
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Page 2 of 14highly purified HIV-1 [12]. One approach involves the
digestion of viral samples using the non-specific serine
protease subtilisin. Subtilisin digestion of HIV-1 pre-
parations eliminates more than 95% of the microvesicle-
associated proteins and removes contaminants docked
to the outside of viruses. The effectiveness of this proto-
col is determined by the size reduction of the gp41
transmembrane envelope glycoprotein. This method is
particularly adapted to the study of proteins inside the
virions. Alternatively, CD45 immunoaffinity depletion of
HIV-1 can be used to isolate viruses from cellular exo-
somes. This technique, which was developed based on
the observation that CD45 membrane molecules are dis-
carded from HIV-1 viruses produced from hematopoie-
tic cells [13], has been previously combined with mass
spectrometry analysis to produce an impressive list of
cell factors packaged into HIV-1 particles produced
from primary macrophages [2,3]. CD45 depletion is
most useful for studies that require the exterior of the
virions to be intact. In any case, electron microscopy
imaging provides a reliable method to discriminate
between assembled viruses and exosomes from a mor-
phological point of view and to validate the presence of
host proteins in virions, as previously reported [14].
Another technical feature to consider when studying
HIV-1-associated cellular factors is the cell type and the
viral isolate or strain used to prepare the biological sam-
ples. The array of packaged cellular proteins may differ
greatly according to the host cell used to propagate the
virus. This aspect has been well documented for mem-
brane molecules embedded in the envelope of virions pro-
duced from various T cell lines. The acquisition of CD55
and CD59 complement decay factors [15], LFA-1 [16] and
MHC class I and II molecules [16,17] is host-dependent.
Distinct incorporation profiles have also been reported
when viruses produced from permanent cell lines or pri-
mary peripheral blood mononuclear cells were analyzed
[15,18]. Regarding cytosolic proteins, this point has not
been comprehensively studied. However, LC-MS/MS ana-
lysis of viruses grown on macrophages [3] failed to detect
the presence of some components that were identified
from viruses grown on T lymphocytes. Notably, ERK-2, a
kinase detected from the HIV-1HZ321 isolate grown in
HUT78 T lymphocytes [6] and from HIV-1ELI viruses pre-
pared from MT4 cells [7], was not detected from HIV-
1NLAD8 grown in primary macrophages [3]. The functional
significance for such difference remains unknown, and its
correlation with the biology of HIV-1 replication in dis-
tinct cell types remains to be analyzed. Nevertheless, the
nature of cellular proteins packaged in HIV-1 needs to be
discussed according to the method in which the viruses
are purified, the nature of the viral strain and the cell type
used for viral production.
Main families of cytoplasmic proteins detected in
HIV-1 virions
The above mentioned strategies have led to the identifi-
cation of a surprisingly large variety of HIV-1 associated
cellular components (referenced in the web-based data-
base http://web.ncifcrf.gov/research/avp/), among which
only a small fraction has been functionally characterized.
A significant proportion of these molecules are glycopro-
teins expressed at the surface of the host cell that become
incorporated into the lipid bilayer surrounding the retro-
viral particle, as extensively reviewed previously [19].
Upon encountering their natural ligand at the surface of
the target cell, they contribute to the initiation and stabi-
lization of the virus-cell contact [20-24], and in some
cases stimulate signaling cascades and various cellular
responses (e.g., inflammation, apoptosis and the modula-
tion of immune responses) [13,25]. Regarding proteins of
cytosolic and nuclear origins, the list of cellular factors
associated with HIV-1 is particularly impressive [3].
Without providing an exhaustive inventory, some
families of proteins have been highlighted.
Cellular chaperones are abundantly incorporated into
HIV-1
The HIV-1-associated protein that was the most exten-
sively studied is certainly the peptidyl-prolyl isomerase
cyclophilin A. Cyclophilin A was detected early as an
essential component for the viral core organization [26].
Approximately 200 molecules are incorporated into one
viral particle, and its interaction with the p24 capsid pro-
tein determines viral infectivity [27,28]. Other proteins
from the chaperone family have been detected in HIV-1
viruses, including heat shock proteins Hsp40, Hsp60,
Hsp90 and Hsp70, and the Pin1 peptidyl-prolyl cis/trans
isomerase [29-31]. The function of HIV-1 associated cha-
perones appears to be generally related to the regulation
of capsid organization, as cyclophilin A, Hsp70 and Pin1
have been proposed to be involved in core reorganization
during assembly and post-entry events [32,33]. This func-
tion is not the only one ascribed to these proteins, parti-
cularly Pin 1. Indeed, Pin1 directly interacts with the
antiviral cytidine deaminase Apobec3G and reduces its
incorporation into viruses [34]. In addition, Pin1 exerts a
stabilizing effect on the retroviral integrase by catalyzing
conformational modifications of the enzyme and pro-
motes HIV-1 genome integration in primary CD4
+ T
lymphocytes [35]. These functions were attributed to
Pin1 in HIV-1 infected cells. Despite the fact that the
contribution of the virus-associated protein in these last
two functions remains to be investigated, it is conceivable
that the presence of Pin1 inside viral particles could assist
early replication by first counteracting residual Apo-
bec3G proteins, which could escape Vif degradation and
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viral integration.
Proteins from trafficking systems
Proteins participating in the trafficking systems of endo-
genous cargoes are packaged within HIV-1 viruses. This
group includes an important variety of components and
regulators of the cytoskeleton network (actin protein,
Arp2/3, HS-1, ezrin, moesin and cofilin) [28,31,36,37].
This group also comprises components of microtubules
(tubulin subunits and the hexokinase-3 molecular motor
[3]). In addition, a series of proteins that participate in
the vesicular trafficking machinery (Tsg101, Alix, Vps28,
Vps4A, Tal and free ubiquitin) [2,3,38] and host factors
required for vesicular transport (notably LAMP1 and
SNARE) [3] and endocytosis (Rab5a [3], vATPase [3],
and clathrin [39]) are packaged into viruses. The pre-
sence of these components is thought to reflect the
hijacking of the cell trafficking machinery when viral
components are transported to the assembly site. Inter-
estingly, actin and moesin, in addition to unrelated cell-
derived proteins, such as EF-1a and NDR1/2 (discussed
below), have been detected in HIV-1 virions as cleavage
products [31,40]. Experiments conducted using defective
HIV-1 mutants suggested that these proteins are digested
by the retroviral protease. However, the functional signif-
icance for the processing of HIV-1-associated cellular
proteins has not been elucidated.
Nuclear proteins incorporated into HIV-1 particles
The viral incorporation of nuclear proteins is typically
illustrated by the selective packaging of histones (H4,
H2B and H3.1) and a number of proteins that interact
with nucleic acids. This group comprises the active his-
tone deacetylase HDAC1 and the chromatin remodeling
protein INI1/HSNF5, which is selectively incorporated
into HIV-1 virions (but excluded from other retroviral
particles) [41,42]. This group also includes the double-
stranded RNA-binding protein Staufen 1 [43], which sup-
ports viral assembly and is packaged through interactions
with HIV-1 genomic RNA and the nucleocapsid domain
of Gag [44]. Finally, a number of nucleic acid-modifying
and -repairing enzymes are also detected in HIV-1 parti-
cles. The cytidine deaminase Apobec3G is incorporated
into Vif-depleted HIV-1 viruses [45]. In wild-type HIV-1,
the incorporation of Apobec3G is counteracted by Vif
through the help of the proteasome degradation system
[46]. Because Apobec3G has demonstrated anti-viral
effects [46], HIV-1 is thought to have acquired the capa-
city to encode proteins counteracting the incorporation
of cellular factors detrimental to replication when they
are packaged into virions. The packaging of uracil DNA
glycosylase 2 (UNG2), a DNA-repair enzyme required for
the excision of uracil misincorporated into genomic
DNA, also illustrates the capacity of HIV-1 to incorpo-
rate nuclear proteins from the host cell [47]. However,
the function of HIV-1-associated UNG2 remains contro-
versial [48]. This protein was alternatively proposed to
assist the reverse transcriptase and to control uracilation
of the neoysnthesized proviral DNA [49], to be dispensa-
ble for HIV-1 replication [50], or to favor the degradation
of the Apobec3G-edited HIV-1 provirus [51]. Interest-
ingly, expression of cellular UNG2 is dramatically
decreased by HIV-1 Vpr, theoretically preventing UNG2
packaging at high levels [52,53]. As UNG2 was reported
to display antiviral activities [51,53], Vpr-mediated degra-
dation could be considered as a defense mechanism
developed to control activity of an antiviral factor likely
to be incorporated into HIV-1.
Protein kinases packaged into HIV-1
In this review, we focused primarily on the class of HIV-1-
associated host cytosolic factors known as protein kinases.
Phosphorylation is one of the major mechanisms through
which the activity of protein factors can be regulated. In
mammalian cells, up to 30% of all proteins may be modi-
fied by phosphorylation. Such regulation impacts multiple
levels, including nucleo-cytoplasmic shuttling, the assem-
bly of macromolecular complexes, DNA-binding capacity
and enzymatic activation. The presence of kinase activities
in viral particles was observed early. The first observations
in the field demonstrated that high levels of protein kinase
activity are packaged in the Rauscher murine leukemia
virus [54] and vaccinia virus [55], and established that the
product of the transforming Rous sarcoma virus exhibits
phosphotransferase capacities [56]. Since these observa-
tions, widespread interest in the study of virus/kinases
relationships has developed. In a significant number of
models, primarily large DNA viruses (such as Herpesviri-
dae, Poxviridae, Baculoviridae), the phosphorylation of
viral proteins can be catalyzed by protein kinases encoded
by the viral genome. The knowledge in this field has
recently been summarized in a complete review [57].
Regarding HIV-1 and related retroviruses, the viral gen-
ome is devoid of genes encoding protein kinase. The pre-
sence of intraviral kinase activity is strictly related to its
capacity to package cellular enzymes into its particles (see
Table 2). This aspect of HIV-1 biology remains poorly
understood. Indeed, while a significant number of studies
performed during the past decade have determined the
capacity of HIV-1 to activate cellular kinases, particularly
following binding of the viral envelope to its receptors or
subsequently to intracellular replication [58-60], little
attention has been devoted to the characterization of
virus-associated kinases and to the study of their func-
tional roles. To date, a small number of tyrosine or serine-
threonine kinases from cellular origin have been reported
to be embedded in HIV-1. Some have received poor
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lck, cdc42, PKC and STAT1 for
which only their presence in the virus has been reported
[3,31]. The kinases that have received the most interest are
ERK2, PKA and NDR1/2 kinases. The knowledge accumu-
lated regarding their functions and their incorporation
into budding structures is discussed below.
ERK2 (HIV-1 produced from lymphoblastoid cell lines;
method of detection: biochemical subtilisin resistance)
The MAPKinase ERK2 was the first protein kinase of cel-
lular origin to be detected within HIV-1 viruses [6,7].
The viral packaging of this protein has been evidenced by
biochemical detection of ERK2 in ultra-purified prepara-
tion of virions and was further confirmed by phosphory-
lation assays performed using a viral lysate as a source of
kinase [6,7]. Its functional role has finally been addressed
by the study of HIV-1 particles produced by cell either
cultured in the presence chemical inhibitors that inter-
fere directly with ERK2 activation or expressing domi-
nant negative forms of ERK2 upstream activators Ras,
Raf or MEK1 [7,61]. This strategy showed that HIV-1
particles devoid of ERK2 activity are poorly infectious.
Such viruses are unable to complete reverse transcription
of the viral genome. They produce reduced levels of
strong-stop DNA, indicating that the virus-associated
kinase is required for an early step of infection. To date,
the exact function of ERK2 packaged in HIV-1 remains
unclear. A number of studies pointed to the capacity of
the kinase to phosphorylate HIV-1 proteins including
Rev [61], Nef [62] and Vif [63,64]. The contribution of
ERK2 in the functional role of Rev and Nef remains
incompletely clarified. Regarding Vif, despite its function
was initially proposed to be regulated by ERK2 mediated
phosphorylation [63], ERK2 has latter been reported to
enhance replication in Vif-independent cell lines [61].
Accordingly, ERK2’s contribution in viral infectivity has
been proposed to be in some extent independent to its
capacity to phosphorylate Vif. Moreover, for all three
proteins, the contribution of the packaged isoform of the
kinase remains far from demonstrated.
Attempts to identify the function of HIV-1-associated
ERK2 have rather focused on its capacity to phosphory-
late the retroviral matrix protein (MA) [7]. A fraction of
MA molecules is phosphorylated in infected cells [65].
Analyzing the functional role of these phosphorylation
events has generated extensive controversy [66-68]. MA
is involved in multiple steps of the HIV-1 replication
cycle. It has been proposed to direct viral proteins traf-
ficking via nuclear import and export functions [69].
More specifically, MA directs targeting of the preintegra-
tion complexes to the nucleus during the early phase of
infection. This function relies on the presence of two
nuclear localization signals in MA [70]. Interestingly, MA
has been reported to localize more predominantly at the
plasma membrane of infected cells when viruses display
reduced ERK2 activity [65]. Consistent with this model,
alanine substitution of four highly conserved serine resi-
dues at positions 9, 67, 72 and 77, which had been identi-
fied as major phosphoacceptor amino acids in MA
(Figure 1), blocked HIV-1 replication at a post-entry step
of infection in permanent cell lines and non-dividing
macrophages [65,71]. The possibility that global MA
phosphorylation unmasks a nuclear localization signal
has been previously proposed for tyrosine phosphoryla-
tion in MA [67]. However, because single serine to ala-
nine substitution of the above mentioned conserved
residues does not markedly influence HIV-1 replication
and has no effect on the MA N-terminal myristate expo-
sure [72], it has rather been suggested that the additive
effect of serine phosphorylation in MA increases the
negative charge of the molecule and promotes the elec-
trostatic repulsion between clusters of positively charged
residues in MA and the inner layer of the plasma mem-
brane [65]. In contradiction with these data, some studies
Table 2 Virion-associated cellular protein kinases and their viral substrates
Family Genus Virus Viral substrate(s) Virus-associated
cellular kinase (s)
Possible function(s) References
Retroviridae Alpharetrovirus AMV (?) 42-46 kDa and 60-64 kDa kinases 10 to 25 kDa viral protein [54,129,130]
RSV (?) Cellular kinase (?) (?) [56]
Betaretrovirus MMTV (?) Cellular kinase (?) (?) [56]
Gammaretrovirus MSV (?) Cellular kinase (?) (?) [131-133]
R-MLV (?) 42-46 kDa and 60-64 kDa Kinases (?) [54,129,130]
FeLV (?) Cellular kinase (?) (?) [56]
Deltaretrovirus HTLV-1 MA ERK2 Virus assembly & release [6,8]
Lentivirus HIV-1 CA, MA, p6 ERK2, PKA, DR1/2, 53 kDa (?), Virus infectivity, uncoating [3,6,7,14,40]
Rev, Nef, Vif p56
lck, PKC, PRP2, Nm23-H1 Virus release, replication (?) [62-64,82,88,85]
SIV (?) ERK2, PKA, PKC (?) [5,76]
FIV (?) ERK2 (?) [76]
Giroud et al. Table 2
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rors the total MA within the cell [73,74]. Altogether these
results suggest that phosphorylation alone does not result
in a shift of MA from a membrane-bound to a mem-
brane-free state. While no consensus has been reached
regarding the precise function of ERK2-mediated MA
phosphorylation, new information on the possible func-
tion of the virus-associated kinase during early HIV-1
replication has been recently published. Based on pre-
vious evidence for the contribution of emerin, a constitu-
ent of the inner nuclear envelope, in the nuclear
translocation and integration of HIV-1 provirus into
chromosomes of cell cycle-arrested primary T lympho-
cytes and macrophages [75], a recent study demonstrated
that HIV-1-associated ERK2 activity, the ERK2-
dependent phosphorylation of emerin and viral DNA
integration are intimately correlated [76]. According to
these results, the phosphorylation of emerin by encapsi-
dated ERK2 would promote the chromatin engagement
of HIV-1 provirus. However, the requirement for emerin
in HIV-1 infectivity is controversial [77,78]. Moreover,
while the study by Bukong et al. clearly demonstrated
that the phosphorylation of emerin can contribute to
processes leading to proviral integration, the respective
contribution of cellular ERK2 and that of the virus-asso-
ciated kinase remains to be formally defined. Indeed,
these results were produced using VSV envelope glyco-
protein-pseudotyped HIV-1, which is unable to trigger
physiological activation signals in the host cell. We and
others have demonstrated that the attachment of the
Figure 1 Schematic representation of HIV-1 Gag and 3D structure of the matrix and p6 proteins. Positions of S9,S 67,S 72 and S77 residues
are indicated in scheme and positioned in three-dimensional structure of the HIV-1 matrix protein [119] (MMDB ID: 53369). Position of T23 is
indicated in scheme and positioned in structure of HIV-1 p6 protein [120] (MMDB ID: 36264).
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MAPKinase signaling pathway in which ERK2 partici-
pates [79-81]. Accordingly, repeating these experiments
with viruses containing an HIV-1 envelope would help to
decipher the relative physiological role of cellular versus
virus-packaged ERK2 in the nuclear import and the post-
nuclear steps of HIV-1 replication.
Finally, searching for ERK2 substrates has evidenced
that the kinase also phosphorylates the L-domain-con-
taining p6 protein [82]. The completion of retroviral bud-
ding requires the recruitment of cellular proteins
associated with the endocytic machinery, namely ESCRT
complexes. For HIV-1, this function is fulfilled by the p6
domain in Gag polyprotein precursor. Canonical PTAP
and YXXLF sequences located at the N-terminus and
C-terminus ends of p6, respectively, are required for
interaction with Tsg101 and Alix/AIP-1 proteins in the
ESCRT1 complex [83,84]. The Tsg101/p6 interaction is
optimized by p6 monoubiquitination and a perturbation
by mean of proteasome inhibitors profoundly interferes
with viral release, morphology and infectivity of secreted
virions [83,84]. Together with H. G. Krausslich’sg r o u p ,
we have reported that the HIV-1 p6 protein is phos-
phorylated by ERK2 both in the context of a Gag poly-
protein precursor and of a mature protein packaged
within HIV-1 virions [82,85]. We have observed that ala-
nine substitution of the unique phosphoacceptor threo-
nine residue identified in p6 significantly reduces viral
particles release and results in the accumulation of
immature virions at the plasma membrane of the host
cell [82], a phenotype very similar to that reported by
others for mutations inhibiting ESCRT1/p6 interactions
[83,86]. In contrast, mimicking p6 phosphorylation
through an aspartic acid substitution at this site increases
the accumulation of mature viruses in intracytoplasmic
vacuoles of the producing cell (L.B., personal communica-
tion). Accordingly, the ERK2-mediated phosphorylation of
p6 may participate in accurate virus-cell membrane
separation and proper viral maturation. Because phos-
phorylation can regulate the recognition of target proteins
by ubiquitin-conjugating enzymes, it can be hypothesized
that ERK2 could regulate HIV-1 late-budding activities by
modifying the recruitment of the vesicular sorting machin-
ery by p6. Interestingly, these observations can be
extended to HTLV-1. Indeed, HTLV-1 budding also relies
on the recruitment of the ESCRT complexes, which
is mediated through interacting motifs located in the
MA protein sequence. We have demonstrated that HTLV-
1 MA is phosphorylated by ERK2 [8]. As observed for
HIV-1, phosphorylation of the L-domain containing
protein is required to regulate HLTV-1 particle assembly
and release. Despite the fact that ERK2 has been equally
detected in purified HTLV-1 and HIV-1 particles
[6,82], it is conceivable that in both viral models, the phos-
phorylation of L-domain-containing proteins is rather
mediated by the cellular form of ERK2 rather than by the
virus-associated isoform of the kinase.
In summary, the data accumulated since the initial
description of ERK2 in HIV-1 particles indicate that the
encapsidation of this cellular kinase is strictly required
for optimal infectivity. Although its function is not
clearly elucidated, virus-associated ERK2 could assist
early steps of HIV-1 replication either by supporting the
establishment of a functional reverse transcription com-
plex or by regulating nuclear import of the preintegra-
tion complexes. Very recent data have shown that ERK2
interacts with the poly-proline motif located near the
cyclophilin binding loop at the N-terminus of HIV-1
CA domain of Gag [9]. This motif, conserved in distinct
retroviruses, including in all subtypes of HIV-1, HIV-2,
SIV, HTLV-I, HTLV-2 and other retroviruses, could
account for the evolutionarily conserved incorporation
of ERK2 in lentiviruses [5-8]. Characterization of this
interaction motif opens a new avenue to investigate the
role virus-associated-ERK2, both in the retroviral cycle
and in HIV-1-induced pathogenesis.
PKA (HIV-1 produced from lymphoblastoid cell lines;
method of detection: biochemical subtilisin resistance)
A second well-documented example of a cellular kinase
packaged within HIV-1 particles is the cAMP-dependent
protein kinase (PKA). In recent years, our group has
demonstrated that PKA is packaged into HIV-1 viruses
[14]. In the cell, PKA is found at the plasma membrane or
associated with subcellular organelles, and it is anchored
to these sites though interactions with AKAP-anchoring
proteins (for review see [87]). In its resting state, the kinase
generally consists of two regulatory subunits and two cata-
lytic subunits. Upon activation, conformational reorganiza-
tion generated at the level of the regulatory subunits favors
the release of the active kinase. In HIV-1 particles, sole
catalytic subunits of PKA have been detected [14]. In
agreement with this observation, the lysate of purified
HIV-1 viruses displays a kinase activity specific for PKA
substrates. Viruses produced from PKA-deficient cell lines
are not infectious [14]. In searching for a possible contri-
bution of the kinase in phosphorylating proteins that are
incorporated into the viral particle, we have found that
PKA interacts with and phosphorylates the p24 capsid
protein [14]. Three serine residues in p24 sequence have
been identified as phosphoacceptor sites [88] (Figure 2A).
To analyze the possible role of PKA-dependent phosphor-
ylation of p24, we have produced HIV-1 mutants unable
to undergo phosphorylation, by alanine substitution at
each phosphoacceptor site. These mutants are impaired
for reverse transcription as observed for PKA-depleted
Giroud et al. Retrovirology 2011, 8:71
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Page 7 of 14HIV-1. Moreover, the assembly and stability of the corre-
sponding capsids are dramatically impaired [88,89].
In mature HIV-1 particles, monomeric p24 assembles
into a lattice of hexameric and pentameric rings to form a
conical core containing the retroviral genome and asso-
ciated proteins. Our approach developed in silico to model
the consequences of phosphorylation at the level of a p24
hexamer has revealed that negative charges generated by
phosphate conjugation at each serine position favors inter-
monomer repulsion or cleavage of important inter-mono-
meric bonds required for preserving the stability of the
hexameric ring of p24 [90] (Figure 3). According to these
results, p24 phosphorylation may be considered as an
event that could modify organization of p24 hexamers and
at a higher order impact the organization of the viral core
edifice. This model has been validated using in vitro
assembly experiments of recombinant p24 with serine-to-
aspartic acid mutations, mimicking constitutive phosphor-
ylation. These results need to be considered in the context
of the reversible processes required for the association of
the retroviral core during the assembly of the viral particle
and for the dissociation of the conical capsid once
delivered into the target cell. Indeed, phosphorylation and
dephosphorylation events are regulators of protein-protein
interactions.
Data accumulated from various models have proven
that kinases from viral or cellular origins act as regulators
of the assembly and disassembly of viral particles by
modulating the association or repulsion of proteins
involved in the structures of the viral cores and in the
packaging of viral genomes. This mechanism is particu-
larly well documented for herpesviruses. Herpes simplex
virus type 1 (HSV-1) tegument protein undergoes phos-
phorylation and dephosphorylation according to the
stage of replication. Moreover, the solubility of the viral
tegument is significantly enhanced in the presence of
ATP-Mg and functional kinase activity [91-94]. In this
model, the dissociation of major tegument proteins in
infected cells is supposed to be initiated by phosphoryla-
tion events mediated both by the UL-13 virus-encoded
serine threonine kinase and by cellular kinases [95].
Additional evidence for a role of phosphorylation in the
packaging and release of viral nucleic acids has been pro-
vided from other viral models, including members of the
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Figure 2 Schematic representations of Gag, capsid protein and VpR protein of HIV-1. Positions of S109,S 149 residues are indicated in
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Page 8 of 14Hepadnaviridae family. The dynamic proteomic study of
mature and immature duck hepatitis B virus (DHBV)
particles has revealed that cell-associated capsid proteins
are highly phosphorylated, while capsids assembled into
cell-free virions are dephosphorylated [96,97]. In this
model, core protein variants, in which serine acceptor
residues have been jointly mutated, display a reduced
capacity for nucleic acid encapsidation [98]. From the
molecular point of view, hydrogen bonds formed by non-
phosphorylated serine have been proposed to stabilize
the quaternary structure of DHBV nucleocapsids during
assembly. Disruption of these bonds, via subsequent ser-
ine phosphorylation, allows the release of genomic DNA
from capsids during the early stages of viral infection.
Similar mechanisms have been reported for the related
human hepatitis B virus (HBV) [99-102]. These events
may involve cellular kinases, such as PKC and PKA, and
RAP ribosome-associated kinases, which are packaged
within the HBV core [103-105]. Finally, this model can
be extended to Togaviridae. In rubella virus, cycles of
alternate phosphorylation of the capsid protein, during
the early stages of replication, and dephosphorylation
during the latter stages, timely regulate the assembly of
the nucleocapsid and the packaging of genomic RNA
[106]. Therefore, sequential phosphorylation clearly
appears to regulate the ordered progression of viral
assembly and disassembly in a number of viral models. In
light of the information available on the packaging of
active PKA into HIV-1 particles and on its contribution
to p24 phosphorylation, this virus-associated kinase may
be considered as a possible regulator acting at the level of
core organization.
In addition to its contribution in p24 phosphorylation,
other functions could potentially be ensured by HIV-1-
associated PKA. Indeed, other proteins, including the
regulatory proteins Nef and Vpr, have been identified as
substrates for the kinase. A single serine residue located
at the N-terminus of Nef is phosphorylated by PKA in
vivo (Figure 2B). Mutation of this residue abrogates the
capacity of Nef to enhance HIV-1 replication in unstimu-
lated primary cells [107]. Similarly, PKA triggers the
phosphorylation of a single serine residue at position 79
in Vpr. This modification is strictly required for Vpr-
dependent cell cycle arrest [108]. Because both Vpr and
Nef are embedded in the viral particle, it is conceivable
that this phosphorylation may involve the virus-asso-
ciated PKA kinase. However, at this time, no experimen-
tal data is available to validate this hypothesis.
Nuclear Dbf2-related kinases (NDR) (Epithelial and
lymphoid cell lines; method of detection: biochemical
subtilisin resistance)
A third family of kinases packaged into HIV virions con-
sists of Dbf2-related kinases. The nuclear NDR1 and cyto-
plasmic NDR2 Dbf2-related kinases participate in the
regulation of cell division and morphology. NDR1/2
kinases remain associated with centrosomal structures
throughout the entire cell cycle and regulate their
Figure 3 Molecular dynamics simulations of unphosphorylated and phosphorylated CA hexamers. Changes observed in the internal
diameter of the CTD of the non phosphorylated (left) and S149-phosphorylated CA hexamer (right) at 4500 ps. For clarity, only the CTD is
represented in ribbons and one color is assigned per monomer [90].
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Page 9 of 14duplication [109]. While endogenous NDR1 has been
detected in HIV-1 preparations, the presence of the NDR2
isoform could be seen in viral particles only when the
tagged kinase was overexpressed in the virus-producing
cell, because of the lack of appropriate detection tools [40].
Interestingly, in HIV-1-infected cells, NDR1 and NDR2 are
cleaved at the C-terminus by the retroviral protease. These
cleaved isoforms are preferentially packaged into viral par-
ticles. The capacity of these cleaved kinases to phosphory-
late HIV-1 proteins remains unknown. In addition, the
consequences of this proteolytic processing on signaling
pathways, controlled by NDR1/2 in the infected cell, have
yet to be investigated. The observation that truncated iso-
forms of NDR kinases relocalize to the nucleus in infected
cells provides strong support for the selective recruitment
of these proteins into viral particles. The mechanisms
underlying the recruitment of cleaved NDR1/2 to the viral
particle and the way HIV-1 takes advantage of the pack-
aged NDR1/2 kinases to assist in viral replication yet
remain to be determined.
Other kinases incorporated in HIV-1 virions
In addition to ERK2, PKA and NDR1/2, additional kinases
have been detected in purified virions using immunoblot-
ting approaches, high-pressure liquid chromatography,
and mass spectrometry analysis. Some kinases remain uni-
dentified, such as a 53 kDa auto-phosphorylable protein
that retains serine/threonine kinase activity and was pro-
posed to target the p24 capsid protein [88]. The apparent
molecular weights of the NDR kinases rendered possible
that they might account for the presence of the anon-
ymous p53 protein in HIV-1. However, the capacity of
NDR1/2 to phosphorylate the viral capsid has not been
investigated. Among these additional kinases are also pro-
tein kinase C [3], phosphoglycerate kinase 1 [3] and p56
lck
tyrosine kinase [31] that was proposed to assist HIV
assembly at the plasma membrane in its cellular forms
[110]. Finally, Nm23-H1 nucleoside diphosphate kinase A
[31], a member of the cytoplasmic SET complex with mul-
tiple activities, including histidine kinase activity, is also
incorporated into HIV-1. Although the function of most
of these proteins in HIV-1 replication has yet to be stu-
died, it is interesting to note that Nm23-H1 has been
shown to protect HIV-1 and the related viruses HIV-2 and
SIV from auto-integration during acute infections when it
is expressed in the infected cell [111]. This function could
be conserved for the packaged isoforms detected in HIV-1
virions and assist the retroviral replication.
Future directions in the study of HIV-1-associated
kinases
In this review, we have summarized the current knowledge
on kinases packaged into HIV-1 and related retroviruses
and on their potential substrates. If data accumulated
clearly argue for the necessity to incorporate cellular
kinases into HIV-1 particles to assist essential steps of
the retroviral life cycle, the complete understanding of
the functional roles played by virus-associated kinases
will require developing new and relevant strategies.
Approaches used so far are based on the study either of
kinase-deficient viruses or on the characterization of
mutant viruses encoding for proteins unable to undergo
phosphorylation. As illustrated above, the production of
viruses depleted of cellular kinase activities has been gen-
erally achieved using chemical inhibitors of cellular kinases
added to the culture medium of virus-producing cells.
However, although these drugs are effective inhibitors of
enzymatic activity, they may have only temporary effects
and generally display poor specificity. Overall, the main
difficulty in this strategy lies in the fact that these inhibi-
tors are not discriminative solely for the kinase molecules
incorporated into viruses. Thus, each study, relying on an
inhibitor-based approach, must consider that the drug
may not only abolish the virus-associated enzymatic activ-
ity, but also potentially interfere with the cellular pool of
kinases assisting in intracellular steps of the replicative
cycle required to produce infectious viral particles. As a
result, the assembly, maturation and organization of the
viral particles produced from kinase-deficient cells need to
be carefully investigated to guarantee that the phenotype
observed for the viruses is strictly linked to the absence of
virus-associated kinase activity and not to any side effect.
This aspect has been particularly controlled in the study of
PKA-deficient viruses [14]. A possible alternative strategy
includes the inhibition of protein-protein or protein-
nucleic acid interactions underlying the incorporation of
cellular kinases into the viral particle. Accordingly, eluci-
dating the mechanisms required for kinase packaging
deserves more attention.
The second strategy used in this field relies on the iden-
tification of viral substrates modified by the packaged
kinases and on the study of viral replication once their
phosphorylation sites are mutated. The most common
approach relies on the generation of alanine mutants
unable to undergo phosphorylation or mutants with acidic
(aspartic acid or glutamic acid) substitutions mimicking
constitutive phosphorylation of potential target sites.
Although it may be informative, this approach fixes the
experimental system into a phosphorylated or unpho-
sphorylated state and accounts neither for dynamic phos-
phorylation and dephosphorylation events nor for the
stoichiometry of the reaction. Accordingly, each model
elaborated using this strategy needs to be refined to
account for the real proportion of molecules phosphory-
lated in vivo. One interesting point is that, in addition to
kinases, HIV-1 incorporates additional cellular proteins
that naturally counteract phosphate-conjugation activities.
Notably, PKC inhibitors and protein phosphatases have
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Page 10 of 14been found to be associated with viral particles [3]. These
data reinforce the idea that phosphorylation and depho-
sphorylation are key regulators of the HIV-1 replicative
cycle and indicate the capacity of the virus to hijack com-
ponents of the cell signaling systems to fulfill appropriate
functions at the site of replication.
Finally, the above mentioned studies point to the neces-
sity to question the physiological role played by the pack-
aged kinases. Recently, a proteomic analysis of SIV virions
revealed that ERK2, PKC and PKA catalytic subunit are
packaged into particles [112]. Moreover, this study estab-
lished that ERK2 is differentially incorporated into viruses
produced from disease-resistant sooty mangabeys and
disease-susceptible rhesus macaques. This observation
strongly argues for a possible role of some packaged
kinases in retrovirus pathogenicity and together with func-
tional studies, suggests their potential interest as targets
for innovative antivirals. The importance of HIV-1-asso-
ciated cellular proteins as therapeutic targets has been sug-
gested more than a decade ago. Antibodies targeting
surface antigens incorporated in the retroviral bilayer
(LFA-1, HLA class I and b2 microglobulin) efficiently
block HIV-1 replication [36,112-115]. The interest in such
a strategy was recently reassessed using LFA1-1 agonists
that potentiated T20 antiviral activity and reduced virus
propagation by decreasing cell-to-cell interactions [116].
Inhibition of cellular kinase activities as a strategy to inhi-
bit intracellular steps of HIV-1 replication has been con-
sidered and is currently under investigation. Much
attention has been focused on several purine derivatives
such as roscovitine inhibiting cyclin-dependent kinases
required for RNA-polymerase II dependent transcription
of integrated viral genes [117]. These molecules have been
reported to inhibit HIV-1 in vitro and in vivo with limited
emergence of resistance [118]. If used to abolish activities
of virus-associated kinases, inhibitor-based strategies must
take into account that the targeted kinases are not essen-
tial for the survival of the uninfected cells or, in the best
scenario, for the survival of the infected cell itself. A more
realistic anti-HIV-1 approach would rather rely on target-
ing either viral proteins used as substrates by virus-asso-
ciated kinases or interactions directing incorporation into
viral particles of cellular kinases indispensable for infectiv-
ity. The capacity of these strategies to reduce the acquisi-
tion of spontaneous mutations generated under the
selective pressure exerted by conventional antivirals will
require evaluation. These aspects will certainly merit
attention when the knowledge on the function and packa-
ging of HIV-1-associated kinases will have been signifi-
cantly improved.
Conclusions
In summary, a limited number of studies have uncovered
the nature and the function of cellular kinases packaged
into HIV-1 particles. While the experimental approaches
developed remain imperfect, these studies have clearly
shown that HIV-1-associated kinases are required for
infectivity and act as key regulators at various steps of
the replicative cycle, including nuclear shuttling of the
preintegration complex and capsid assembly/disassembly.
These functions are regulated through phosphorylation
of HIV-1-encoded proteins. Given the variety of cellular
kinases detected in viral particles, this family of proteins
is expected to regulate additional steps of the HIV-1 life
cycle. Analyzing their function will certainly provide new
information regarding the biology of HIV-1. In addition,
the capacity of HIV-1-associated kinases to target pro-
teins in the newly infected cells has also been proposed
although not formally demonstrated. This issue needs to
be examined carefully to determine the contribution of
virus-associated kinases in HIV-1 induced pathogenesis.
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